A human monoclonal antibody with neutralizing activity against highly divergent influenza subtypes.
Identifieur interne : 000155 ( PubMed/Corpus ); précédent : 000154; suivant : 000156A human monoclonal antibody with neutralizing activity against highly divergent influenza subtypes.
Auteurs : Nicola Clementi ; Donata De Marco ; Nicasio Mancini ; Laura Solforosi ; Guisella J. Moreno ; Larisa V. Gubareva ; Vasiliy Mishin ; Andrea Di Pietro ; Elisa Vicenzi ; Antonio G. Siccardi ; Massimo Clementi ; Roberto BurioniSource :
- PloS one [ 1932-6203 ] ; 2011.
English descriptors
- KwdEn :
- Alanine (genetics), Animals, Antibodies, Monoclonal (chemistry), Antibodies, Neutralizing (chemistry), Cell Line, Cluster Analysis, Dogs, Glycoproteins (chemistry), Hemagglutinins, Viral (chemistry), Humans, Influenza Vaccines (therapeutic use), Influenza, Human (metabolism), Influenza, Human (prevention & control), Models, Molecular, Molecular Conformation, Mutagenesis, Site-Directed, Neutralization Tests, Orthomyxoviridae (genetics), Orthomyxoviridae (immunology), Phylogeny, Protein Binding.
- MESH :
- chemical , chemistry : Antibodies, Monoclonal, Antibodies, Neutralizing, Glycoproteins, Hemagglutinins, Viral.
- chemical , genetics : Alanine.
- chemical , therapeutic use : Influenza Vaccines.
- genetics : Orthomyxoviridae.
- immunology : Orthomyxoviridae.
- metabolism : Influenza, Human.
- prevention & control : Influenza, Human.
- Animals, Cell Line, Cluster Analysis, Dogs, Humans, Models, Molecular, Molecular Conformation, Mutagenesis, Site-Directed, Neutralization Tests, Phylogeny, Protein Binding.
Abstract
The interest in broad-range anti-influenza A monoclonal antibodies (mAbs) has recently been strengthened by the identification of anti-hemagglutinin (HA) mAbs endowed with heterosubtypic neutralizing activity to be used in the design of "universal" prophylactic or therapeutic tools. However, the majority of the single mAbs described to date do not bind and neutralize viral isolates belonging to highly divergent subtypes clustering into the two different HA-based influenza phylogenetic groups: the group 1 including, among others, subtypes H1, H2, H5 and H9 and the group 2 including, among others, H3 subtype. Here, we describe a human mAb, named PN-SIA28, capable of binding and neutralizing all tested isolates belonging to phylogenetic group 1, including H1N1, H2N2, H5N1 and H9N2 subtypes and several isolates belonging to group 2, including H3N2 isolates from the first period of the 1968 pandemic. Therefore, PN-SIA28 is capable of neutralizing isolates belonging to subtypes responsible of all the reported pandemics, as well as other subtypes with pandemic potential. The region recognized by PN-SIA28 has been identified on the stem region of HA and includes residues highly conserved among the different influenza subtypes. A deep characterization of PN-SIA28 features may represent a useful help in the improvement of available anti-influenza therapeutic strategies and can provide new tools for the development of universal vaccinal strategies.
DOI: 10.1371/journal.pone.0028001
PubMed: 22162996
Links to Exploration step
pubmed:22162996Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A human monoclonal antibody with neutralizing activity against highly divergent influenza subtypes.</title><author><name sortKey="Clementi, Nicola" sort="Clementi, Nicola" uniqKey="Clementi N" first="Nicola" last="Clementi">Nicola Clementi</name><affiliation><nlm:affiliation>Laboratorio di Microbiologia e Virologia, Università Vita-Salute San Raffaele, Milano, Italia.</nlm:affiliation></affiliation></author><author><name sortKey="De Marco, Donata" sort="De Marco, Donata" uniqKey="De Marco D" first="Donata" last="De Marco">Donata De Marco</name></author><author><name sortKey="Mancini, Nicasio" sort="Mancini, Nicasio" uniqKey="Mancini N" first="Nicasio" last="Mancini">Nicasio Mancini</name></author><author><name sortKey="Solforosi, Laura" sort="Solforosi, Laura" uniqKey="Solforosi L" first="Laura" last="Solforosi">Laura Solforosi</name></author><author><name sortKey="Moreno, Guisella J" sort="Moreno, Guisella J" uniqKey="Moreno G" first="Guisella J" last="Moreno">Guisella J. Moreno</name></author><author><name sortKey="Gubareva, Larisa V" sort="Gubareva, Larisa V" uniqKey="Gubareva L" first="Larisa V" last="Gubareva">Larisa V. Gubareva</name></author><author><name sortKey="Mishin, Vasiliy" sort="Mishin, Vasiliy" uniqKey="Mishin V" first="Vasiliy" last="Mishin">Vasiliy Mishin</name></author><author><name sortKey="Di Pietro, Andrea" sort="Di Pietro, Andrea" uniqKey="Di Pietro A" first="Andrea" last="Di Pietro">Andrea Di Pietro</name></author><author><name sortKey="Vicenzi, Elisa" sort="Vicenzi, Elisa" uniqKey="Vicenzi E" first="Elisa" last="Vicenzi">Elisa Vicenzi</name></author><author><name sortKey="Siccardi, Antonio G" sort="Siccardi, Antonio G" uniqKey="Siccardi A" first="Antonio G" last="Siccardi">Antonio G. Siccardi</name></author><author><name sortKey="Clementi, Massimo" sort="Clementi, Massimo" uniqKey="Clementi M" first="Massimo" last="Clementi">Massimo Clementi</name></author><author><name sortKey="Burioni, Roberto" sort="Burioni, Roberto" uniqKey="Burioni R" first="Roberto" last="Burioni">Roberto Burioni</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011</date><idno type="RBID">pubmed:22162996</idno><idno type="pmid">22162996</idno><idno type="doi">10.1371/journal.pone.0028001</idno><idno type="wicri:Area/PubMed/Corpus">000155</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000155</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">A human monoclonal antibody with neutralizing activity against highly divergent influenza subtypes.</title><author><name sortKey="Clementi, Nicola" sort="Clementi, Nicola" uniqKey="Clementi N" first="Nicola" last="Clementi">Nicola Clementi</name><affiliation><nlm:affiliation>Laboratorio di Microbiologia e Virologia, Università Vita-Salute San Raffaele, Milano, Italia.</nlm:affiliation></affiliation></author><author><name sortKey="De Marco, Donata" sort="De Marco, Donata" uniqKey="De Marco D" first="Donata" last="De Marco">Donata De Marco</name></author><author><name sortKey="Mancini, Nicasio" sort="Mancini, Nicasio" uniqKey="Mancini N" first="Nicasio" last="Mancini">Nicasio Mancini</name></author><author><name sortKey="Solforosi, Laura" sort="Solforosi, Laura" uniqKey="Solforosi L" first="Laura" last="Solforosi">Laura Solforosi</name></author><author><name sortKey="Moreno, Guisella J" sort="Moreno, Guisella J" uniqKey="Moreno G" first="Guisella J" last="Moreno">Guisella J. Moreno</name></author><author><name sortKey="Gubareva, Larisa V" sort="Gubareva, Larisa V" uniqKey="Gubareva L" first="Larisa V" last="Gubareva">Larisa V. Gubareva</name></author><author><name sortKey="Mishin, Vasiliy" sort="Mishin, Vasiliy" uniqKey="Mishin V" first="Vasiliy" last="Mishin">Vasiliy Mishin</name></author><author><name sortKey="Di Pietro, Andrea" sort="Di Pietro, Andrea" uniqKey="Di Pietro A" first="Andrea" last="Di Pietro">Andrea Di Pietro</name></author><author><name sortKey="Vicenzi, Elisa" sort="Vicenzi, Elisa" uniqKey="Vicenzi E" first="Elisa" last="Vicenzi">Elisa Vicenzi</name></author><author><name sortKey="Siccardi, Antonio G" sort="Siccardi, Antonio G" uniqKey="Siccardi A" first="Antonio G" last="Siccardi">Antonio G. Siccardi</name></author><author><name sortKey="Clementi, Massimo" sort="Clementi, Massimo" uniqKey="Clementi M" first="Massimo" last="Clementi">Massimo Clementi</name></author><author><name sortKey="Burioni, Roberto" sort="Burioni, Roberto" uniqKey="Burioni R" first="Roberto" last="Burioni">Roberto Burioni</name></author></analytic><series><title level="j">PloS one</title><idno type="eISSN">1932-6203</idno><imprint><date when="2011" type="published">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Alanine (genetics)</term><term>Animals</term><term>Antibodies, Monoclonal (chemistry)</term><term>Antibodies, Neutralizing (chemistry)</term><term>Cell Line</term><term>Cluster Analysis</term><term>Dogs</term><term>Glycoproteins (chemistry)</term><term>Hemagglutinins, Viral (chemistry)</term><term>Humans</term><term>Influenza Vaccines (therapeutic use)</term><term>Influenza, Human (metabolism)</term><term>Influenza, Human (prevention & control)</term><term>Models, Molecular</term><term>Molecular Conformation</term><term>Mutagenesis, Site-Directed</term><term>Neutralization Tests</term><term>Orthomyxoviridae (genetics)</term><term>Orthomyxoviridae (immunology)</term><term>Phylogeny</term><term>Protein Binding</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Antibodies, Neutralizing</term><term>Glycoproteins</term><term>Hemagglutinins, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Alanine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Orthomyxoviridae</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Orthomyxoviridae</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Cell Line</term><term>Cluster Analysis</term><term>Dogs</term><term>Humans</term><term>Models, Molecular</term><term>Molecular Conformation</term><term>Mutagenesis, Site-Directed</term><term>Neutralization Tests</term><term>Phylogeny</term><term>Protein Binding</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The interest in broad-range anti-influenza A monoclonal antibodies (mAbs) has recently been strengthened by the identification of anti-hemagglutinin (HA) mAbs endowed with heterosubtypic neutralizing activity to be used in the design of "universal" prophylactic or therapeutic tools. However, the majority of the single mAbs described to date do not bind and neutralize viral isolates belonging to highly divergent subtypes clustering into the two different HA-based influenza phylogenetic groups: the group 1 including, among others, subtypes H1, H2, H5 and H9 and the group 2 including, among others, H3 subtype. Here, we describe a human mAb, named PN-SIA28, capable of binding and neutralizing all tested isolates belonging to phylogenetic group 1, including H1N1, H2N2, H5N1 and H9N2 subtypes and several isolates belonging to group 2, including H3N2 isolates from the first period of the 1968 pandemic. Therefore, PN-SIA28 is capable of neutralizing isolates belonging to subtypes responsible of all the reported pandemics, as well as other subtypes with pandemic potential. The region recognized by PN-SIA28 has been identified on the stem region of HA and includes residues highly conserved among the different influenza subtypes. A deep characterization of PN-SIA28 features may represent a useful help in the improvement of available anti-influenza therapeutic strategies and can provide new tools for the development of universal vaccinal strategies.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22162996</PMID><DateCompleted><Year>2012</Year><Month>07</Month><Day>20</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>12</Issue><PubDate><Year>2011</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS ONE</ISOAbbreviation></Journal><ArticleTitle>A human monoclonal antibody with neutralizing activity against highly divergent influenza subtypes.</ArticleTitle><Pagination><MedlinePgn>e28001</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0028001</ELocationID><Abstract><AbstractText>The interest in broad-range anti-influenza A monoclonal antibodies (mAbs) has recently been strengthened by the identification of anti-hemagglutinin (HA) mAbs endowed with heterosubtypic neutralizing activity to be used in the design of "universal" prophylactic or therapeutic tools. However, the majority of the single mAbs described to date do not bind and neutralize viral isolates belonging to highly divergent subtypes clustering into the two different HA-based influenza phylogenetic groups: the group 1 including, among others, subtypes H1, H2, H5 and H9 and the group 2 including, among others, H3 subtype. Here, we describe a human mAb, named PN-SIA28, capable of binding and neutralizing all tested isolates belonging to phylogenetic group 1, including H1N1, H2N2, H5N1 and H9N2 subtypes and several isolates belonging to group 2, including H3N2 isolates from the first period of the 1968 pandemic. Therefore, PN-SIA28 is capable of neutralizing isolates belonging to subtypes responsible of all the reported pandemics, as well as other subtypes with pandemic potential. The region recognized by PN-SIA28 has been identified on the stem region of HA and includes residues highly conserved among the different influenza subtypes. A deep characterization of PN-SIA28 features may represent a useful help in the improvement of available anti-influenza therapeutic strategies and can provide new tools for the development of universal vaccinal strategies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Clementi</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Laboratorio di Microbiologia e Virologia, Università Vita-Salute San Raffaele, Milano, Italia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Marco</LastName><ForeName>Donata</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Mancini</LastName><ForeName>Nicasio</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Solforosi</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Moreno</LastName><ForeName>Guisella J</ForeName><Initials>GJ</Initials></Author><Author ValidYN="Y"><LastName>Gubareva</LastName><ForeName>Larisa V</ForeName><Initials>LV</Initials></Author><Author ValidYN="Y"><LastName>Mishin</LastName><ForeName>Vasiliy</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Di Pietro</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Vicenzi</LastName><ForeName>Elisa</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Siccardi</LastName><ForeName>Antonio G</ForeName><Initials>AG</Initials></Author><Author ValidYN="Y"><LastName>Clementi</LastName><ForeName>Massimo</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Burioni</LastName><ForeName>Roberto</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>12</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006023">Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006389">Hemagglutinins, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>OF5P57N2ZX</RegistryNumber><NameOfSubstance UI="D000409">Alanine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000409" MajorTopicYN="N">Alanine</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016000" MajorTopicYN="N">Cluster Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004285" MajorTopicYN="N">Dogs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006023" MajorTopicYN="N">Glycoproteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006389" MajorTopicYN="N">Hemagglutinins, Viral</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008968" MajorTopicYN="N">Molecular Conformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016297" MajorTopicYN="N">Mutagenesis, Site-Directed</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009975" MajorTopicYN="N">Orthomyxoviridae</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010802" MajorTopicYN="N">Phylogeny</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>08</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>10</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22162996</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0028001</ArticleId><ArticleId IdType="pii">PONE-D-11-14840</ArticleId><ArticleId IdType="pmc">PMC3230632</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Science. 2011 Aug 12;333(6044):850-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21798894</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Invest. 2010 May;120(5):1663-73</Citation><ArticleIdList><ArticleId IdType="pubmed">20389023</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Virol. 1985;85(3-4):209-16</Citation><ArticleIdList><ArticleId IdType="pubmed">2411245</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2008;3(12):e3942</Citation><ArticleIdList><ArticleId IdType="pubmed">19079604</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral Res. 2010 Dec;88(3):249-55</Citation><ArticleIdList><ArticleId IdType="pubmed">20849879</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2004 Sep;78(17):9233-42</Citation><ArticleIdList><ArticleId IdType="pubmed">15308718</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2009 Dec 15;200(12):1870-3</Citation><ArticleIdList><ArticleId IdType="pubmed">19911992</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral Res. 2008 Apr;78(1):91-102</Citation><ArticleIdList><ArticleId IdType="pubmed">18328578</ArticleId></ArticleIdList></Reference><Reference><Citation>New Microbiol. 2009 Oct;32(4):319-24</Citation><ArticleIdList><ArticleId IdType="pubmed">20128437</ArticleId></ArticleIdList></Reference><Reference><Citation>Infect Immun. 1990 Oct;58(10):3407-14</Citation><ArticleIdList><ArticleId IdType="pubmed">2401569</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 1993 May;67(5):2552-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7682624</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2007 Jun 28;25(27):5086-96</Citation><ArticleIdList><ArticleId IdType="pubmed">17544181</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2010 Sep 10;285(37):28403-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20538598</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Pathog. 2010 Feb;6(2):e1000796</Citation><ArticleIdList><ArticleId IdType="pubmed">20195520</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2011 Feb;17(2):283-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21291607</ArticleId></ArticleIdList></Reference><Reference><Citation>Public Health Rep. 2010 Apr;125 Suppl 3:16-26</Citation><ArticleIdList><ArticleId IdType="pubmed">20568566</ArticleId></ArticleIdList></Reference><Reference><Citation>MBio. 2010 May 18;1(1):null</Citation><ArticleIdList><ArticleId IdType="pubmed">20689752</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Public Health. 2010;10:724</Citation><ArticleIdList><ArticleId IdType="pubmed">21106057</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2009 Apr 10;324(5924):246-51</Citation><ArticleIdList><ArticleId IdType="pubmed">19251591</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2010 Mar 30;399(1):144-52</Citation><ArticleIdList><ArticleId IdType="pubmed">20096915</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2009 Jun;15(6):966-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19523305</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Pathog. 2010;6(7):e1000990</Citation><ArticleIdList><ArticleId IdType="pubmed">20628565</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Immunol. 2010 May;10(5):301-16</Citation><ArticleIdList><ArticleId IdType="pubmed">20414204</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Microbiol. 2008 Feb;6(2):143-55</Citation><ArticleIdList><ArticleId IdType="pubmed">18197170</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1995 Apr 15;154(8):3975-84</Citation><ArticleIdList><ArticleId IdType="pubmed">7706736</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Struct Mol Biol. 2009 Mar;16(3):265-73</Citation><ArticleIdList><ArticleId IdType="pubmed">19234466</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2009 May 26;27(25-26):3345-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19200846</ArticleId></ArticleIdList></Reference><Reference><Citation>Euro Surveill. 2009 Jul 30;14(30):19287</Citation><ArticleIdList><ArticleId IdType="pubmed">19643062</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2009 Oct 24;374(9699):1417; author reply 1417-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19854362</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2010;5(2):e9106</Citation><ArticleIdList><ArticleId IdType="pubmed">20161706</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2009 Aug 13;27(37):5043-53</Citation><ArticleIdList><ArticleId IdType="pubmed">19559118</ArticleId></ArticleIdList></Reference><Reference><Citation>J Hepatol. 2008 Aug;49(2):299-300</Citation><ArticleIdList><ArticleId IdType="pubmed">18554744</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2010 Nov 18;363(21):2036-44</Citation><ArticleIdList><ArticleId IdType="pubmed">21083388</ArticleId></ArticleIdList></Reference><Reference><Citation>Virol J. 2010;7:351</Citation><ArticleIdList><ArticleId IdType="pubmed">21118546</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2010 Dec;16(12):1389-91</Citation><ArticleIdList><ArticleId IdType="pubmed">21135852</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharmacokinet. 2010 Aug;49(8):493-507</Citation><ArticleIdList><ArticleId IdType="pubmed">20608753</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2007 Sep 28;25(39-40):6852-62</Citation><ArticleIdList><ArticleId IdType="pubmed">17719149</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2010 Dec 15;51(12):1442-4</Citation><ArticleIdList><ArticleId IdType="pubmed">21067353</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2008;3(10):e3423</Citation><ArticleIdList><ArticleId IdType="pubmed">18923648</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2011 Aug 12;333(6044):843-50</Citation><ArticleIdList><ArticleId IdType="pubmed">21737702</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000155 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000155 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:22162996
|texte= A human monoclonal antibody with neutralizing activity against highly divergent influenza subtypes.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:22162996" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a H2N2V1
| This area was generated with Dilib version V0.6.33. |  |